Abbvie Inc banner

Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 205.07 USD -0.56% Market Closed
Market Cap: $362.6B

Relative Value

The Relative Value of one ABBV stock under the Base Case scenario is 222.86 USD. Compared to the current market price of 205.07 USD, Abbvie Inc is Undervalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ABBV Relative Value
Base Case
222.86 USD
Undervaluation 8%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

ABBV Competitors Multiples
Abbvie Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Abbvie Inc
NYSE:ABBV
362.5B USD 5.9 86.6 14.4 20
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Amgen Inc
NASDAQ:AMGN
187.5B USD 5.1 24.3 14.1 14.1
US
Gilead Sciences Inc
NASDAQ:GILD
170.3B USD 5.8 20 12.5 15.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.3B USD 9.6 29.2 21.9 22.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.5B USD 5.4 17.2 12.6 14.4
AU
CSL Ltd
ASX:CSL
66.8B AUD 3.1 34.3 11.3 14.3
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.3B USD 11.1 131.9 73.8 82
NL
argenx SE
XBRU:ARGX
35.8B EUR 10 32.1 34.6 35.3
P/S Multiple
Revenue Growth P/S to Growth
US
Abbvie Inc
NYSE:ABBV
Average P/S: 3 063 003.6
5.9
9%
0.7
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.8
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
10%
0.5
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
11.1
34%
0.3
NL
argenx SE
XBRU:ARGX
10
27%
0.4
P/E Multiple
Earnings Growth PEG
US
Abbvie Inc
NYSE:ABBV
Average P/E: 47
86.6
97%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.3
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.2
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
13%
1.3
AU
CSL Ltd
ASX:CSL
34.3
10%
3.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
131.9
84%
1.6
NL
argenx SE
XBRU:ARGX
32.1
32%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Abbvie Inc
NYSE:ABBV
Average EV/EBITDA: 24.4
14.4
12%
1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.1
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
18%
0.7
AU
CSL Ltd
ASX:CSL
11.3
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
73.8
67%
1.1
NL
argenx SE
XBRU:ARGX
34.6
50%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Abbvie Inc
NYSE:ABBV
Average EV/EBIT: 27.3
20
23%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.1
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.5
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
23%
0.6
AU
CSL Ltd
ASX:CSL
14.3
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
82
69%
1.2
NL
argenx SE
XBRU:ARGX
35.3
51%
0.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett